EUCTR2021-001703-32-BG招募中1 期
A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Non-pharmacologically Treated Acromegaly - PATHFNDR-2
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 98
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Willing and able to provide written informed consent prior to any study-related procedures.
- •2. Willing and able to comply with the study procedures as specified in the protocol and comply with the study treatment administration.
- •3. Subjects =18 years of age at the time of Screening who fall into 1 of the following 3 groups are eligible to participate in the study.
- •Medically naïve group (Group 1): Those who have not been previously treated with acromegaly medications (including LA-SRLs) who at
- •Screening have IGF-1 =1.3×ULN (the lower limit for eligibility is mean IGF-1 of 1.25×ULN when rounded to 2 decimal places) confirmed by the central laboratory test at S1. Group 1 subjects must have had at least 1 pituitary surgery 3 months or more prior to Screening.
- •Previously Treated group (no treatment within previous 4 months) (Group 2): Subjects who have last been treated with acromegaly
- •medications at least 4 months prior to Screening and who have IGF-1 =1.3×ULN (the lower limit for eligibility is mean IGF-1 of 1.25 when rounded to 2 decimal places) confirmed by the central laboratory test at S1.
- •Washout group (Group 3): Subjects at Screening who are receiving stable treatment (no change in dose for 3 months prior to Screening) with
- •octreotide or lanreotide monotherapy, who have IGF-1 =1.0×ULN (the upper limit for eligibility is mean IGF-1 of 1.04 when rounded to 2 decimal places) at Screening Visit 1 and are willing to washout of their medication during the Screening Period. Any form of pretrial octreotide or lanreotide monotherapy (long- or short-acting [SC, IM, or oral]) can be washed out and will determine the duration of the Screening Period. After informed consent is provided, the subject should not receive further pretrial acromegaly medication. IGF-1 must rise at least 30% from the first Screening Visit to the last Screening Visit and to =1.1×ULN (the lower limit for eligibility is mean IGF-1 of 1.05 when rounded to 2 decimal
- •places) confirmed by the central laboratory test at S2 or S3, if needed) to qualify for enrollment.
- •4. Previous diagnosis of acromegaly confirmed by the Investigator and approved by the Medical Monitor. This requires evaluable documentation
- •of a pituitary adenoma.
- •5. If currently using thyroid hormone therapy, the subject should be adequately treated based on clinical status and free thyroxine
- •concentration measured during Screening and on a stable dose of thyroid hormone for at least 8 weeks prior to Screening.
- •6. Females who engage in heterosexual intercourse must be of non childbearing potential, defined as either surgically sterile (i.e., hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), OR be postmenopausal with at least 1 year of amenorrhea, OR must agree to use either a highly effective or a clinically acceptable method of contraception from the beginning of Screening until at least 30 days after the last dose of study drug.
- •7. If the subject is male, the subject should agree to use a condom when sexually active with a female partner of childbearing potential from Screening until at least 30 days after the last dose of study drug (or be surgically sterile [i.e., vasectomy with documentation]; or remain abstinent [when this is in line with the preferred and usual lifestyle]. Male subjects should also agree to not donate sperm for the duration of the study and until at least 30 days after the last dose of study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this a
排除标准
- •1.History of ineffectiveness or significant intolerance of octreotide or lanreotide treatment, as determined by the Investigator.
- •2.History of pituitary radiation therapy within 3 years of Screening.
- •3.Subjects with adrenal insufficiency, diabetes insipidus, or central hypogonadism who are not receiving adequate hormone replacement therapy at the time of Screening, as determined by the Investigator.
- •4.High risk pituitary tumor pattern as defined by:
- •Compression of the optic chiasm or invasion of adjacent brain structures (other than sphenoid sinus or cavernous sinus)
- •History of tumor growth within 1 year after surgery or radiation (unless it occurred during a period of medical therapy interruption)
- •Anticipated requirement for neurosurgical intervention or radiation therapy within the time course of the study.
- •Pituitary carcinoma currently or at any time in the past.
- •5.History of major surgery/surgical therapy for any cause within 4 weeks prior to Screening.
- •6.Diabetes mellitus treated with insulin for less than 6 weeks prior to the study entry, or with change in total daily insulin dose by >15% within 6 weeks prior to Screening.
- •7.History of unstable angina or acute myocardial infarction within the 12 weeks preceding the Screening Visit or other clinically significant cardiac disease at the time of screening as judged by the Investigator.
- •8.Known history of hepatitis B or human immunodeficiency virus, or active hepatitis C infection.
- •9.Active malignant disease within the last 5 years with exception of basal and squamous cell carcinoma of the skin with complete local excision and resected carcinoma in situ of cervix.
- •10.Concomitant mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study, and/or evidence of poor compliance with medical instructions.
- •11.Use of the following medications as outlined:
- •Any history of acromegaly medication use (G1 only)
- •Lanreotide depot or octreotide LAR (within 16 weeks before Screening) (G2 only)
- •Pasireotide LAR (within 24 weeks prior to Screening)
- •Pegvisomant (within 16 weeks before Screening)
- •Dopamine agonists (within 16 weeks before Screening)
- •Any combination of 2 or more acromegaly medications at Screening
- •Proton pump inhibitors (from start of Screening) until the end of the study
- •12.Current use of oral estrogen replacement therapy for <12 weeks prior to Screening.
- •13.Current use of medications that are strong inducers of CYP3A4 within 2 weeks prior to Screening
- •14.Known allergy or hypersensitivity to any of the test materials or related compounds.
- •15.Active COVID-19 confirmed or suspected based on clinical symptoms
- •16.Symptomatic cholelithiasis
- •17.Clinically significant concomitant disease including but not limited to cardiovascular disease, severe renal insufficiency (estimated glomerular filtration rate <30 mL/min/1.73 m2), or significant liver disease (including cirrhosis)
- •18.Clinically significant abnormal findings during the Screening Period or any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardize the subject’s safety or ability to complete the study
- •19.Systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg during Screening. If the initial measurement is out of range, it may be repeated 2 more times after 15 minutes and the last assessment should be used to determine subject’s eligibility
- •20.Resting (at least 10 minutes) palpated pulse rate
研究者
相似试验
进行中（未招募）
1 期
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study where subjects with non-pharmacologically treated acromegaly will be randomly allocated to receive either paltusotine or placebo.AcromegalyEUCTR2021-001703-32-HUCrinetics Pharmaceuticals, Inc.98
进行中（未招募）
1 期
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study where subjects with non-pharmacologically treated acromegaly will be randomly allocated to receive either paltusotine or placebo.AcromegalyEUCTR2021-001703-32-ESCrinetics Pharmaceuticals, Inc.98
招募中
1 期
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study where subjects with non-pharmacologically treated acromegaly will be randomly allocated to receive either paltusotine or placebo.MedDRA version: 20.0Level: PTClassification code 10000599Term: AcromegalySystem Organ Class: 10014698 - Endocrine disordersAcromegalyEUCTR2021-001703-32-PLCrinetics Pharmaceuticals, Inc.98
尚未招募
3 期
A Study to Evaluate the Safety and Effectiveness of Paltusotine for the Treatment of AcromegalyCTRI/2022/09/045510Crinetics Pharmaceuticals Inc
进行中（未招募）
1 期
Combined treatement with human albumin and intravenous immunoglobulin in Alzheimer diseaseEUCTR2011-001598-25-ESINSTITUTO GRIFOLS, S.A.350